Salvadora Persica Root
Phase 1Small molecule
Salvadora Persica Root is one of 33 small molecule programs targeting Chronic Periodontitis. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
65 competitors in Chronic Periodontitis
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Minocin
TTriax
Approved
Singulair
OOrganon and Co
Approved
Crestor
AstraZenecaPhase 3
Propolis
IIndonesia University
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Glucophage
EMD SeronoPhase 3
Fosamax
OOrganon and Co
Phase 3
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Salvadora Persica Root. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- KKing Saud University